Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

Dell’Aquila, Emanuela; Cremolini, Chiara; Zeppola, Tea; Lonardi, Sara; Bergamo, Francesca; Masi, Gianluca; Stellato, Marco; Marmorino, Federica; Schirripa, Marta; Urbano, Federica; Ronzoni, Monica; Tomasello, Gianluca; Zaniboni, Alberto; Racca, Patrizia; Buonadonna, Angela; Allegrini, Giacomo; Fea, Elena; Donato, Samantha Di; Chiara, Silvana; Tonini, Giuseppe; Tomčíková, Daniela; Boni, Luca; Falcone, Alfredo; Santini, Daniele

doi:10.1093/annonc/mdy004

Cited by 103 publications

(90 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the initial analysis, we found that the mGPS was significantly lower and that NLR and tumor markers (CEA and CA19‐9) tended to be lower in the T‐B group than in the T group. Because mGPS , NLR , CEA , and CA19‐9 are prognostic factors for patients with mCRC, our findings suggest that patients in the T group had slightly poorer prognosis in the initial analysis. Using propensity score matched analysis to correct for any biases, we found that the median OS was significantly longer in the T‐B group than in the T group (14.4 months vs. 6.1 months, p < .001) and that there was a significant correlation between Bmab and OS (HR, 0.37; p = .018) after adjusting for age and mGPS, similar to the initial analysis.…”

Section: Discussionmentioning

confidence: 75%

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study

et al. 2019

View full text Add to dashboard Cite

Objective TAS‐102 is effective for treating patients with metastatic colorectal cancer (mCRC). This study determined whether combining bevacizumab (Bmab) with TAS‐102 improves clinical outcomes in refractory mCRC. Patients and Methods We retrospectively analyzed data from Japanese patients with refractory mCRC who received TAS‐102 (35 mg/m2, twice a day) with (T‐B group) or without Bmab (TAS‐102 monotherapy; T group) between July 2014 and December 2018. The primary endpoint was median overall survival (OS), and secondary endpoints were median time to treatment failure, overall response rate, and the incidence of adverse events. Clinical outcomes were compared using propensity score matched analysis. Results Data from 57 patients were analyzed (T‐B group: 21 patients, T group: 36 patients). Median OS was significantly longer in the T‐B group than the T group (14.4 months vs. 4.5 months, p < .001). Cox proportional hazard analysis showed that combination therapy with Bmab was significantly correlated with OS. Propensity score matched analysis confirmed that the median OS was significantly longer in the T‐B group than the T group (14.4 months vs. 6.1 months, p = .006) and that there was a significant correlation between Bmab and OS. The incidence of hypertension (grade ≥2) as an adverse event was significantly higher in the T‐B group than the T group (23.8% vs. 0.0%, p = .005), whereas other adverse events were comparable between the two groups. Conclusion Treatment with Bmab in combination with TAS‐102 is significantly associated with improved clinical outcomes in patients with mCRC refractory to standard therapies. Implications for Practice Combining bevacizumab (Bmab) with TAS‐102 significantly improved overall survival and several prognostic indicators in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies, with manageable toxicities. Treatment with Bmab in combination with TAS‐102 is significantly associated with improved clinical outcomes in patients with mCRC.

show abstract

Section: Discussionmentioning

confidence: 75%

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The role of systemic inflammation has been studied in several cancers; the most investigated inflammation markers are: C-reactive protein (CRP) and albumin combined as the modified Glasgow Prognostic Score (mGPS), neutrophil-lymphocyte ratio (NLR), plateletlymphocyte ratio (PLR), white cell count and CRP as the prognostic index (PI) and the combination of albumin and lymphocyte count in prognostic nutritional index (PNI). Those markers have been studied in several solid tumors [91], such as breast cancer [92], hepatocellular carcinoma [93], and colorectal cancer, in both resected [91] and metastatic patients [94].…”

Section: Inflammatory Markersmentioning

confidence: 99%

Prognostic and predictive factors in pancreatic cancer

et al. 2020

View full text Add to dashboard Cite

Pancreatic cancer is one of the leading causes of cancer death worldwide. Its high mortality rate has remained unchanged for years. Radiotherapy and surgery are considered standard treatments in early and locally advanced stages. Chemotherapy is the only option for metastatic patients. Two treatment regimens, i. e. the association of 5-fluorouracil-irinotecan-oxaliplatin (FOLFIRINOX) and the association of nabpaclitaxel with gemcitabine, have been shown to improve outcomes for metastatic pancreatic adenocarcinoma patients. However, there are not standardized predictive biomarkers able to identify patients who benefit most from treatments. CA19-9 is the most studied prognostic biomarker, its predictive role remains unclear. Other clinical, histological and molecular biomarkers are emerging in prognostic and predictive settings. The aim of this review is to provide an overview of prognostic and predictive markers used in clinical practice and to explore the most promising fields of research in terms of treatment selection and tailored therapy in pancreatic cancer.

show abstract

“…[1][2][3] The peripheral neutrophil-to-lymphocyte ratio (NLR) is a well-known inflammatory marker. Several authors have previously reported that a high NLR is significantly associated with poor survival in solid cancers, [4][5][6][7][8][9][10][11][12][13][14] including head and neck squamous cell carcinoma and breast cancer. However, whether the NLR affects prognosis in patients with parotid cancer remains unknown; therefore, the current study aimed to clarify this question.…”

Section: Introductionmentioning

confidence: 99%

<p>Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients</p>

Cheng

Liu

Niu

et al. 2019

CMAR

View full text Add to dashboard Cite

Background: To analyze the value of the pretreatment neutrophil-to-lymphocyte ratio (NLR) in the survival of patients with parotid cancer. Methods: In total, 249 patients were enrolled. Information including age, sex, pretreatment NLR, and pathologic variables such as, tumor stage, intraparotid node (IPN) metastasis, and follow-up findings was extracted and analyzed. Results: IPN metastasis was noted in 45 (18.1%) patients, and the mean NLR was 2.48, with a range from 1.5 to 6.1. The NLR was significantly associated with tumor stage, disease stage, and disease grade. A total of 73 patients died of the disease, and the 10-year disease-specific survival (DSS) rate was 62%. In patients with an NLR<2.48, the 10-year DSS rate was 68%; in patients with an NLR≥2.48, the 10-year DSS rate was 58%, and the difference was significant (P=0.006). Cox model analysis showed that the NLR was an independent prognostic factor for DSS. Conclusion: The long-term survival of primary parotid cancer patients is relatively favorable, and the pretreatment NLR is significantly associated with prognosis.

show abstract

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

Abstract: This study confirmed the prognostic role of NLR in mCRC pts treated with bevacizumab plus chemotherapy in the first line, showing the worse prognosis of pts with high NLR. The advantage of the triplet is independent of NLR at baseline.

Cited by 103 publications

References 36 publications

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study

Prognostic and predictive factors in pancreatic cancer

<p>Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients</p>

Contact Info

Product

Resources

About